Market Forecasts for Immuno-Oncology Diagnostics Including Executive/Consultant Guides and Customized Forecasting/Analysis

1.1 Situation Analysis
1.2 Guide for Executives and Marketing Staff
1.3 Guide for Investment Analysts and Management Consultants

2.1 What are Immuno-Oncology Diagnostics?
2.2 Immuno-oncology - the looming cure
2.2.1 Immuno-oncology Diagnostics Takes a Leading Role
2.3 Market Definition
2.3.1 Market Size
2.3.2 Currency
2.3.3 Years
2.4 Methodology
2.4.1 Methodology
2.4.2 Sources
2.4.3 Authors
2.5 Perspective: Healthcare and the IVD Industry
2.5.1 Global Healthcare Spending
2.5.2 Spending on Diagnostics
2.5.3 Important Role of Insurance for Diagnostics

3.1 The Immune System
3.1.1 Innate immune system
3.1.1.1 Surface barriers
3.1.1.2 Inflammation
3.1.1.3 Complement system
3.1.1.4 Cellular barriers
3.1.1.5 Natural killer cells
3.1.2 Adaptive immune system
3.1.2.1 Lymphocytes
3.1.2.2 Killer T cells
3.1.2.3 Helper T cells
3.1.2.4 Gamma delta T cells
3.1.2.5 B lymphocytes and antibodies
3.1.3 Tumor immunology - the immune surveillance system
3.2 Immuno Oncology Diagnostics
3.2.1 Checkpoint Assays
3.2.1.1 Outlook for Checkpoint Assays
3.2.2 Cytokine Assays
3.2.2.1 Outlook for Cytokine Assays
3.2.3 Genomic Germline
3.2.3.1 Outlook for Genomic Germline
3.2.4 Genomic Tumour
3.2.4.1 Outlook for Genomic Tumour
3.2.5 Tumor Microenviroment
3.2.5.1 Outlook for Tumor Microenvironment
3.2.6 Others
3.2.6.1 Outlook for Other Diagnostics

4.1 Players in a Dynamic Market
4.1.1 Academic Research Lab
4.1.2 Diagnostic Test Developer
4.1.3 Instrumentation Supplier
4.1.4 Chemical/Reagent Supplier
4.1.5 Pathology Supplier
4.1.6 Independent Clinical Laboratory
4.1.7 Public National/regional Laboratory
4.1.8 Hospital Laboratory
4.1.9 Physicians Office Lab (POLS)
4.1.10 Audit Body
4.1.11 Certification Body

5.1 Factors Driving Growth
5.1.1 Outcome potential
5.1.2 Companion Diagnostics
5.1.3 Funding
5.1.4 Technology Environment
5.1.5 Target Solutions
5.2 Factors Limiting Growth
5.2.1 Complex Role of Diagnostics
5.2.2 Clinical Trials Role
5.2.3 Protocols
5.3 Diagnostic Technology Development
5.3.1 Combinations - Issues and Complexity
5.3.2 Shifting Role of Diagnostics
5.3.3 Multiplexing and Foundation One
5.3.4 The Disruption Dynamic
5.3.5 The Race for Biomarkers
5.3.6 The Next Five Years

6.1 Recent Developments - Importance and How to Use This Section
6.1.1 Importance of These Developments
6.1.2 How to Use This Section
6.2 Thermo Fisher and Bayer to Develop CDx for Cancer Therapies
6.3 ClearNote Health Expands Into Immunotherapy Monitoring
6.4 Foundation Medicine to Collaborate on CDx for Lung Cancer
6.5 Qiagen and Myriad Genetics Partner to Develop Cancer CDx
6.6 Lung Cancer Data Heralds Shift for Hummingbird Dx
6.7 PamGene Awarded €7.5M for Immunotherapy Test
6.8 Freenome Acquires Oncimmune
6.9 Guardant Health Gets Coverage for Liquid Biopsy Treatment Response Test
6.10 BostonGene to Develop Sarcoma-Specific Liquid Biopsy
6.11 Exact Sciences OncoExTra Therapy Selection Test
6.12 Integrated DNA Technologies Buys NGS Research Assays
6.13 Navignostics Using Single-Cell Spatial Proteomics
6.14 New Reference Samples for NGS-Based Cancer Tests
6.15 Spatial Proteomics Panel for Immuno-Oncology
6.16 dMMR, MSI Assays for Immunotherapy Patient Selection
6.17 OncoHost Expands Prophet Platform Research
6.18 Protein-Based Liquid Biopsy Panel Assesses TME
6.19 Oncimmune Announces Sixfold Revenue Increase
6.20 Mayo Clinic, Personalis Ink Collaboration
6.21 Lucence Liquid Biopsy Test Tracks Immune Treatment ctDNA Changes
6.22 Qiagen, OncXerna Close Companion Dx Development Deal
6.23 Natera Test to Guide Therapy for Bladder Cancer
6.24 Veracyte Halio Acquisition to Boost Immuno-oncology Activity
6.25 Freenome Eyes New Dx Possibilities
6.26 Oncocyte Data has Potential as Immunotherapy Response Predictor
6.27 OncoDNA use HalioDx to Expand into North America
6.28 Adaptive Biotechnologies, Q2 Solutions Agreement for ImmunoSeq Assay
6.29 Qiagen Expands Immuno-Oncology Portfolio
6.30 Immune Profiling System Redirected to Fight COVID-19
6.31 IncellDx Awarded PD-L1 Detection Patent
6.32 FDA Approves CDx for Trastuzumab
6.33 Promega Nabs CE Mark for Microsatellite Instability IVD
6.34 ArcherDx partners with AstraZeneca for Immuno-Oncology
6.35 Germline Results Guides Precision Therapy
6.36 Agilent PD-L1 Assay Gets FDA Approval
6.37 Bayer, OrigiMed Form Companion Diagnostic Development Alliance
6.38 Bio-Me to Develop Microbiome Biomarker Test for Cancer Immunotherapy
6.39 SkylineDx, BioInvent Collaborate to Characterize Predictive Immunological Signatures
6.40 Biocare Medical Launches 7 Novel IVD Antibodies

7.1 10x Genomics, Inc.
7.2 Abbott Laboratories
7.3 AccuraGen Inc.
7.4 Adaptive Biotechnologies
7.5 Aethlon Medical
7.6 Agilent
7.7 Anchor Dx
7.8 ANGLE plc
7.9 ARUP Laboratories
7.10 AVIVA Systems Biology
7.11 Baylor Miraca Genetics Laboratories
7.12 Beckman Coulter Diagnostics (Danaher)
7.13 Becton, Dickinson and Company
7.14 Berkley Lights
7.15 BGI Genomics Co. Ltd
7.16 Bioarray Genetics
7.17 Biocartis
7.18 Biocept, Inc.
7.19 Biodesix Inc.
7.20 BioFluidica
7.21 BioGenex
7.22 BioIVT
7.23 Biolidics Ltd
7.24 bioMérieux Diagnostics
7.25 Bioneer Corporation
7.26 Bio-Rad Laboratories, Inc.
7.27 Bio-Reference Laboratories
7.28 Bio-Techne
7.29 Bioview
7.30 Bristol-Myers Squibb
7.31 Burning Rock
7.32 Cardiff Oncology
7.33 Caris Molecular Diagnostics
7.34 Castle Biosciences, Inc.
7.35 CellCarta
7.36 CellMax Life
7.37 Cepheid (Danaher)
7.38 Charles River Laboratories
7.39 Circulogene
7.40 Cizzle Biotech
7.41 Clearbridge Biomedics
7.42 Clinical Genomics
7.43 Cytolumina Technologies Corp.
7.44 Datar Cancer Genetics Limited
7.45 Diagnologix LLC
7.46 Diasorin S.p.A.
7.47 Dxcover
7.48 Element Biosciences
7.49 Enzo Biochem
7.50 Epic Sciences
7.51 Epigenomics AG
7.52 Eurofins Scientific
7.53 Fabric Genomics
7.54 Fluxion Biosciences (Cell Microsystems)
7.55 Freenome
7.56 FUJIFILM Wako Diagnostics
7.57 Fujirebio
7.58 Fyr Diagnostics
7.59 GeneFirst Ltd.
7.60 Genetron Holdings
7.61 GenomOncology
7.62 GILUPI Nanomedizin
7.63 Guardant Health
7.64 HansaBiomed
7.65 HTG Molecular Diagnostics
7.66 iCellate
7.67 ICON PLC
7.68 Illumina
7.69 Incell Dx
7.70 Inivata
7.71 INOVIQ
7.72 Invitae Corporation
7.73 Invivogen
7.74 Invivoscribe
7.75 J&J Innovative Medicine
7.76 KEW
7.77 Lucence Health
7.78 Lunglife AI Inc
7.79 MDNA Life SCIENCES, Inc.
7.80 MDx Health
7.81 Menarini Silicon Biosystems
7.82 Mesa Laboratories, Inc.
7.83 Millipore Sigma
7.84 Miltenyi Biotec
7.85 miR Scientific
7.86 Myriad Genetics
7.87 Nanostring
7.88 NantHealth, Inc.
7.89 Natera
7.90 NeoGenomics
7.91 NGeneBio
7.92 Novogene
7.93 Oncimmune
7.94 Oncocyte
7.95 OncoDNA
7.96 Oncohost
7.97 Oxford Nanopore Technologies
7.98 PamGene
7.99 Panagene
7.100 Personalis
7.101 PGDx (Labcorp)
7.102 Precipio
7.103 PrecisionMed
7.104 Predicine
7.105 Predictive Oncology
7.106 Prenetics
7.107 Promega
7.108 Qiagen
7.109 QuidelOrtho
7.110 Rarecells SAS
7.111 RareCyte
7.112 Recursion Pharma
7.113 Revvity
7.114 Roche Diagnostics
7.115 Screencell
7.116 Sherlock Biosciences
7.117 Siemens Healthineers
7.118 simfo GmbH
7.119 Singlera Genomics Inc.
7.120 Singular Genomics
7.121 Singulomics
7.122 SkylineDx
7.123 Standard BioTools
7.124 Stilla Technologies
7.125 Sysmex Inostics
7.126 Tempus Labs, Inc.
7.127 Thermo Fisher Scientific
7.128 Todos Medical
7.129 Ultima Genomics
7.130 Veracyte
7.131 VolitionRX
7.132 Vortex Biosciences

8.1 Global Market Overview by Country
8.1.1 Table - Global Market by Country
8.1.2 Chart - Global Market by Country
8.2 Global Market by Assay Type - Overview
8.2.1 Table - Global Market by Assay Type
8.2.2 Chart - Global Market by Assay Type - Base/Final Year Comparison
8.2.3 Chart - Global Market by Assay Type - Base Year
8.2.4 Chart - Global Market by Assay Type - End Year
8.2.5 Chart - Global Market by Assay Type - Share by Year
8.2.6 Chart - Global Market by Assay Type - Segments Growth
8.3 Global Market by Technology - Overview
8.3.1 Table - Global Market by Technology
8.3.2 Chart - Global Market by Technology - Base/Final Year Comparison
8.3.3 Chart - Global Market by Technology - Base Year
8.3.4 Chart - Global Market by Technology - End Year
8.3.5 Chart - Global Market by Technology - Share by Year
8.3.6 Chart - Global Market by Technology - Segments Growth
8.4 Global Market by Customer - Overview
8.4.1 Table - Global Market by Customer
8.4.2 Chart - Global Market by Customer - Base/Final Year Comparison
8.4.3 Chart - Global Market by Customer - Base Year
8.4.4 Chart - Global Market by Customer - End Year
8.4.5 Chart - Global Market by Customer - Share by Year
8.4.6 Chart - Global Market by Customer - Segments Growth

9.1 Checkpoint
9.1.1 Table Checkpoint - by Country
9.1.2 Chart - Checkpoint Growth
9.2 Cytokine
9.2.1 Table Cytokine - by Country
9.2.2 Chart - Cytokine Growth
9.3 Germline Genetic
9.3.1 Table Germline Genetic - by Country
9.3.2 Chart - Germline Genetic Growth
9.4 Genetic Tumor
9.4.1 Table Genetic Tumor - by Country
9.4.2 Chart - Genetic Tumor Growth
9.5 Tumor Microenvironment
9.5.1 Table Tumor Microenvironment - by Country
9.5.2 Chart - Tumor Microenvironment Growth
9.6 Other
9.6.1 Table Other - by Country
9.6.2 Chart - Other Growth

10.1 NGS
10.1.1 Table NGS - by Country
10.1.2 Chart - NGS Growth
10.2 PCR
10.2.1 Table PCR - by Country
10.2.2 Chart - PCR Growth
10.3 Fish/IHC
10.3.1 Table Fish/IHC - by Country
10.3.2 Chart - Fish/IHC Growth
10.4 Chem/IA
10.4.1 Table Chem/IA - by Country
10.4.2 Chart - Chem/IA Growth
10.5 Other Technology
10.5.1 Table Other Technology - by Country
10.5.2 Chart - Other Technology Growth

11.1 Pharma
11.1.1 Table Pharma - by Country
11.1.2 Chart - Pharma Growth
11.2 Clinic
11.2.1 Table Clinic - by Country
11.2.2 Chart - Clinic Growth
11.3 Other Customer Genetic
11.3.1 Table Other Customer - by Country
11.3.2 Chart - Other Customer Growth

12.1 Prevalence of Cancer Treatments
12.2 Growth of Approved IVD Test Menu
12.3 Growth of Approved Average IVD Test Fee
12.4 The Most Used IVD Assays
12.5 The Highest Grossing Assays
12.6 Laboratory Fees Schedule

Table 1 List of Cancers by Mortality
Table 2 Overview of Innate and Adaptive Immunity
Table 3 FDA Approved Monoclonal Antibodies in Cancer treatment
Table 4 FDA Approved Companion diagnostics in Cancer treatment
Table 5 Market Players by Type
Table 6 Five Factors Driving Growth
Table 7 Three Factors Limiting Growth
Table 8 - Global Market by Region
Table 9 Global Market by Assay Type
Table 10 Global Market by Technology
Table 11 Global Market by Customer
Table 12 Checkpoint by Country
Table 13 Cytokine by Country
Table 14 Germline Genetic by Country
Table 15 Genetic Tumor by Country
Table 16 Tumor Microenvironment by Country
Table 17 Other by Country
Table 18 NGS by Country
Table 19 PCR by Country
Table 20 Fish/IHC by Country
Table 21 Chem/IA by Country
Table 22 Other Technology by Country
Table 23 Pharma by Country
Table 24 Clinic by Country
Table 25 Other Customer by Country
Table 26 The Most Common Assays
Table 27 Largest Revenue Assays
Table 28 Clinical Lab Fee Schedule

Figure 1 Cancer Death Rates - USA, CDC
Figure 2 Global healthcare Spending
Figure 3 The Lab Test Pie
Figure 4 Helper T Cell Roles
Figure 5 Antibody Diagram
Figure 6 Macrophages attack a Cancer Cell
Figure 7 The Tumour Micro Environment
Figure 8 The Road to Diagnostics
Figure 9 Comparing IO Diagnostic and Traditional Testing
Figure 10 Growth rates of IO DiagnosticTechnologies
Figure 11 Global Market Density Chart
Figure 12 Global Market by Assay Type - Base vs. Final
Figure 13 Global Market by Assay Type Base Year
Figure 14 Global Market by Assay Type End Year
Figure 15 Assay Type Share by Year
Figure 16 Assay Type Segments Growth
Figure 17 Global Market by Technology - Base vs. Final
Figure 18 Global Market by Technology Base Year
Figure 19 Global Market by Technology End Year
Figure 20 Technology Share by Year
Figure 21 Technology Segments Growth
Figure 22 Global Market by Customer - Base vs. Final
Figure 23 Global Market by Customer Base Year
Figure 24 Global Market by Customer End Year
Figure 25 Customer Share by Year
Figure 26 Customer Segments Growth
Figure 27 Checkpoint Growth
Figure 28 Cytokine Growth
Figure 29 Germline Genetic Growth
Figure 30 Genetic Tumor Growth
Figure 31 Tumor Microenvironment Growth
Figure 32 Other Growth
Figure 33 NGS Growth
Figure 34 PCR Growth
Figure 35 Fish/IHC Growth
Figure 36 Chem/IA Growth
Figure 37 Other Technology Growth
Figure 38 Pharma Growth
Figure 39 Clinic Growth
Figure 40 Other Customer Growth
Figure 41 Prevalence of Cancer Treatments
Figure 42 IVD Test Menu Growth
Figure 43 IVD Test Average Fees - A Ten Year View